Condition category
Eye Diseases
Date applied
27/10/2006
Date assigned
29/11/2006
Last edited
10/05/2012
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Mr Adnan Tufail

ORCID ID

Contact details

Moorfields Eye Hospital NHS Foundation Trust
162 City Road
London
EC1V 2PD
United Kingdom

Additional identifiers

EudraCT number

2006-001544-31

ClinicalTrials.gov number

Protocol/serial number

REC reference number 06/Q0504/46. EudraCT number 2006-001544-31

Study information

Scientific title

Acronym

ABC

Study hypothesis

To determine the efficacy and safety of intravitreal Avastin® (bevacizumab) intravitreal injections compared to usual care (verteporfin photodynamic therapy, Macugen® or sham) in treating choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD).

Please note that, as of 24/09/2008, the anticipated end date of this trial has been updated from 01/12/2007 to 05/12/2008.

Ethics approval

Moorfields and Whittington Local Research Ethics Committee, date of approval 14 July 2006 (ref: 06/Q0504/46).

Added as of 06/10/2008: An additional approval has been granted from the Guy's Research Ethics Committee on the 5th April 2007 to allow recruitment at additional trial sites within the UK (ref: 07/Q0704/20).

Study design

Prospective, double masked, randomised, controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD)

Intervention

1. Intravitreal Avastin® (bevacizumab) with placebo PDT where necessary to maintain masking
2. Verteporfin PDT with sham intravitreal injection
3. Intravitreal Macugen® (pegaptanib sodium)
4. Sham intravitreal injection

Intervention type

Drug

Phase

Phase III

Drug names

Avastin® (bevacizumab), verteporfin, Macugen® (pegaptanib sodium)

Primary outcome measures

The proportion of subjects who gain 15 letters (3 lines) or more of best corrected visual acuity score at the 12 month timepoint compared with baseline, based on the ETDRS visual acuity chart and assessment at a starting distance of 4 m.

Secondary outcome measures

Secondary outcome measures amended as of 24/09/2008:
1. The proportion of subjects who lose fewer than 15 letters (approximately 3 lines), the proportion who have gained 5 letters or more (1 line), and the proportion who have gained 10 letters or more (2 lines) in the best corrected visual acuity score at 12 months compared with baseline, based on the ETDRS visual acuity chart and assessment at a starting distance of 4 m
2. The proportion of patients who meet these visual criteria at 6 months
3. To evaluate the safety and tolerability of intravitreal injections of Avastin® given every 6 weeks
4. Mean change in central OCT thickness
5. If the study is continued after the analysis of data at 12 month timepoint, after the second treatment year of the study, the same objectives will be analysed on unmasked data

Previous secondary outcome measures:
1. The proportion of subjects who lose fewer than 15 letters (approximately three lines) and the proportion who have gained five letters or more (one line) in the best corrected visual acuity score at 12 months compared with baseline, based on the ETDRS visual acuity chart and assessment at a starting distance of 4 m
2. The proportion of patients who meet these visual criteria at six months
3. To evaluate the safety and tolerability of intravitreal injections of Avastin® given every six weeks
4. Mean change in central OCT thickness
5. If study is continued after the analysis of data at 12 month time point then after the second treatment year of the study, the same objectives will be analysed on unmasked data

Overall trial start date

11/08/2006

Overall trial end date

05/12/2008

Reason abandoned

Eligibility

Participant inclusion criteria

1. Aged over 50 years
2. Primary or subfoveal CNV lesions secondary to AMD in the study eye
3. An occult lesion must have presumed evidence of disease progression, defined as one or more of the following:
a. deterioration of best corrected vision by one Snellen line or five letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart within the past three months due to progression of CNV
b. presence of sub- or intra-retinal blood
c. growth of lesion size on the angiogram by more than 10% in the past three months
AND evidence of increased central macular thickness on Optical Coherence Tomography (OCT)
4. Area of sub-retinal blood less than 50% of total lesion area
5. Best corrected visual acuity, using ETDRS charts, of 20/40 (6/12) to 20/320 (6/96) Snellen equivalent in the study eye
6. Total lesion size less than 12 disc areas including all contiguous lesion components
7. Area of fibrosis less than 25% of the total lesion area

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

130

Participant exclusion criteria

Ocular:
1. Sub-retinal haemorrhage in the study eye that involves the centre of the fovea, if the size of the haemorrhage is either more than 50% of the total lesion area or more than one disc areas in size
2. Subfoveal fibrosis or atrophy in the study eye
3. CNV in either eye due to causes other than AMD, such as ocular histoplasmosis, trauma, or pathologic myopia
4. Retinal pigment epithelial tear involving the macula in the study eye
5. Prior treatment with external-beam radiation therapy, Transpupillary Thermal Therapy (TTT), thermal laser, or Photo-Dynamic Therapy (PDT) in the study eye or history of submacular surgery or other surgical intervention for AMD in the study eye
6. PDT in the non-study eye less than seven days preceding day zero
7. Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (Macugen®, Avastin®, anecortave acetate, protein kinase C inhibitors, etc.)
8. Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye
9. Amblyopia, infective conjunctivitis or scleritis, glaucoma, corneal disease, inflammatory eye disease
10. Diabetic retinopathy more than ‘mild nonproliferative’ in the fellow eye as defined by the ETDRS or any diabetic maculopathy
11. Intraocular surgery (including cataract surgery) in the study eye within two months preceding day zero
12. Aphakia or absence of the posterior capsule in the study eye
13. Previous violation of the posterior capsule in the study eye is also excluded unless it occurred as a result of Yttrium Aluminum Garnet (YAG) posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
14. Spherical equivalent of the refractive error in the study eye demonstrating more than -8 diopters of myopia or signs of pathologic myopia with a refraction of 4-8 diopters
15. For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye cannot exceed -8 diopters of myopia

Systemic:
1. Recent stroke (last six months), or cardiac event (last six months), uncontrolled angina or uncontrolled hypertension
2. Current treatment for active systemic infection
3. Unable to give informed consent
4. Anticoagulant treatment (anti-platelet drugs allowed)
5. Fluorescein or Indo-Cyanine Green (ICG) allergy
6. Pre-menopausal women not using adequate contraception; the following are considered effective means of contraception: surgical sterilisation, use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an Intra-Uterine Device (IUD), or contraceptive hormone implant or patch

Recruitment start date

11/08/2006

Recruitment end date

05/12/2008

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Moorfields Eye Hospital NHS Foundation Trust
London
EC1V 2PD
United Kingdom

Sponsor information

Organisation

Moorfields Eye Hospital NHS Foundation Trust (UK)

Sponsor details

162 City Road
London
EC1V 2PD
United Kingdom
+44 (0)20 7566 2816
sue.lydeard@moorfields.nhs.uk

Sponsor type

Government

Website

http://www.moorfields.nhs.uk/Home

Funders

Funder type

Government

Funder name

The Special Trustees of Moorfields Eye Hospital NHS Foundation Trust (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20538634
2. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21310910
3. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22281826

Publication citations

  1. Results

    Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W, , Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study., BMJ, 2010, 340, c2459.

  2. Results

    Patel PJ, Chen FK, Da Cruz L, Rubin GS, Tufail A, , Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration., Invest. Ophthalmol. Vis. Sci., 2011, 52, 6, 3089-3093, doi: 10.1167/iovs.10-6208.

  3. Results

    Keane PA, Heussen FM, Ouyang Y, Mokwa N, Walsh AC, Tufail A, Sadda SR, Patel PJ, Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration., Invest. Ophthalmol. Vis. Sci., 2012, 53, 3, 1152-1161, doi: 10.1167/iovs.11-8130.

Additional files

Editorial Notes